Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Ustekinumab – therapeutic use"'
1
Akademický článek
Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis
Autor: Inês Raposo, Andreia Bettencourt, Luiz Leite, Manuela Selores, Tiago Torres
Publikováno v: Acta Médica Portuguesa, Vol 32, Iss 3, Pp 214-218 (2019)
Introduction: Ustekinumab is a monoclonal antibody directed against the p40 subunit common to both IL-12 and IL-23 cytokines. Although the evidence of ustekinumab efficacy and safety in clinical trials is extensively recognized, data on its use in cl
Externí odkaz: https://doaj.org/article/82c5c712cb1a4d908dfc43ee5d091385
Zobrazit plný text záznamu
2
Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy
Autor: Anne Grosen, Emanuelle Bellaguarda, Ingela Liljeqvist-Soltic, Mette Mejlby Hansen, Anne-Bine Skytte, Mette Julsgaard, Stephen B Hanauer, Jens Kelsen
Publikováno v: Grosen, A, Bellaguarda, E, Liljeqvist-Soltic, I, Mejlby Hansen, M, Skytte, A-B, Julsgaard, M, Hanauer, S B & Kelsen, J 2022, ' Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy ', Inflammatory Bowel Diseases, vol. 28, no. 10, pp. 1603-1606 . https://doi.org/10.1093/ibd/izac028
Lay Summary We demonstrate that ustekinumab does not adversely affect semen quality or sex hormones in male patients. Ustekinumab is not detectable in semen and poses no risk to partners. Our observations support a recommendation to continue ustekinu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cad9c4596a406a02e62ed6defb8d934
https://pure.au.dk/portal/da/publications/normal-sperm-dna-integrity-in-patients-with-inflammatory-bowel-disease-on-ustekinumab-maintenance-therapy(ecf9d55e-a408-489a-bbed-93fe51baf2b7).html
Zobrazit plný text záznamu
3
Ustekinumab no Tratamento de Psoríase Moderada a Grave: Experiência em 116 Doentes da Prática Clínica
Autor: Andreia Bettencourt, Manuela Selores, Tiago Torres, Inês Raposo, Luiz Fernando Carvalho Leite
Publikováno v: Acta Médica Portuguesa; v. 32, n. 3 (2019): Março; 214-218
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
Acta Médica Portuguesa, Vol 32, Iss 3, Pp 214-218 (2019)
Ustekinumab is a monoclonal antibody directed against the p40 subunit common to both IL-12 and IL-23 cytokines. Although the evidence of ustekinumab efficacy and safety in clinical trials is extensively recognized, data on its use in clinical practic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dea94b874246c681e7cb1a7891b7b748
https://doi.org/10.20344/amp.10728
Zobrazit plný text záznamu
4
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy
Autor: Luc Manlay, Gilles Boschetti, Bruno Pereira, Bernard Flourié, Michel Dapoigny, Maud Reymond, Elisa Sollelis, Claire Gay, Mathilde Boube, Anthony Buisson, Stéphane Nancey
Publikováno v: Alimentary Pharmacology & Therapeutics (Suppl)
Alimentary Pharmacology & Therapeutics (Suppl), 2021, 53 (12), pp.1289-1299. ⟨10.1111/apt.16377⟩
International audience; Background The best option between vedolizumab and ustekinumab after anti-tumour necrosis factor (TNF) failure remains unclear in Crohn's disease.Aims To compare the short- and long-term effectiveness of vedolizumab and usteki
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2652049eb780af3af66c93ab6ce48e7
https://pubmed.ncbi.nlm.nih.gov/34170547
Zobrazit plný text záznamu
5
Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model
Autor: Mikkel Østergaard, Simon Krabbe, Bente Glintborg, Mette Nørgaard, Kathrine Lederballe Grøn, Merete Lund Hetland, Frank Mehnert, Dorte Ejg Jarbøl
Publikováno v: Krabbe, S, Grøn, K L, Glintborg, B, Nørgaard, M, Mehnert, F, Jarbøl, D E, Østergaard, M & Hetland, M L 2021, ' Risk of serious infections in arthritis patients treated with biological drugs : a matched cohort study and development of prediction model ', Rheumatology (Oxford, England), vol. 60, no. 8, pp. 3834-3844 . https://doi.org/10.1093/rheumatology/keaa876
Krabbe, S, Grøn, K L, Glintborg, B, Nørgaard, M, Mehnert, F, Jarbøl, D E, Østergaard, M & Hetland, M L 2021, ' Risk of serious infections in arthritis patients treated with biological drugs : a matched cohort study and development of prediction model ', Rheumatology, vol. 60, no. 8, pp. 3834-3844 . https://doi.org/10.1093/rheumatology/keaa876
Objectives Serious infection is a concern for patients with inflammatory joint diseases treated with biological drugs (bDMARDs). The objectives were to compare risk of serious infection, defined as infection leading to hospitalization, in patients in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::488ef68537652c680c0490daf788a33f
https://pubmed.ncbi.nlm.nih.gov/33493342
Zobrazit plný text záznamu
6
Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis:nationwide results from the DERMBIO registry
Autor: Lone Skov, T N Dam, Lars Iversen, Lone Hvid, Alexander Egeberg, Robert Gniadecki, L.E. Bryld
Publikováno v: Egeberg, A, Iversen, L, Gniadecki, R, Hvid, L, Dam, T N, Bryld, L E & Skov, L 2017, ' Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis : nationwide results from the DERMBIO registry ', Journal of the European Academy of Dermatology and Venereology, vol. 31, no. 7, pp. 1183–1187 . https://doi.org/10.1111/jdv.14200
Egeberg, A, Iversen, L, Gniadecki, R, Hvid, L, Dam, T N, Bryld, L E & Skov, L 2017, ' Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis-nationwide results from the DERMBIO registry ', Journal of the European Academy of Dermatology and Venereology, vol. 31, pp. 1183-1187 . https://doi.org/10.1111/jdv.14200
BACKGROUND: While safety and efficacy of ustekinumab and secukinumab, monoclonal antibodies approved for psoriasis, are described in clinical trials, data on their real-life application are lacking.OBJECTIVE: We compared the characteristics of patien
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8f697acc39ed908c4cad2c550f45968
https://portal.findresearcher.sdu.dk/da/publications/5433ebc2-5d79-4515-a0b6-ae03788d8dae
Zobrazit plný text záznamu
8
LIJEČENJE PSORIJATIČNOG ARTRITISA BIOLOŠKIM I CILJANIM SINTETSKIM LIJEKOVIMA
Autor: Branimir Anić, Ivan Padjen
Publikováno v: Reumatizam
Volume 64
Issue suppl. 1
Terapijske opcije u psorijatičnom artritisu znatno su unaprijeđene u novom tisućljeću. Dolazak bioloških lijekova otvorio je vrata uspješnijem liječenju svih domena psorijatičnog artritisa, uključujući periferni i aksijalni artritis, daktil
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______951::6876a6cc0af0a7f6606985acfbd71152
https://hrcak.srce.hr/188339
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Interleukin 23–Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris
Autor: Daniel Hohl, Olivier Demaria, Nikhil Yawalkar, Curdin Conrad, Laurence Feldmeyer, Emmanuel Laffitte, Anna Mennella, Michel Gilliet, Alessio Mylonas
Publikováno v: JAMA dermatology, vol. 153, no. 4, pp. 304-308
JAMA Dermatology, Vol. 153, No 4 (2017) pp. 304-308
Importance Treatment of pityriasis rubra pilaris (PRP) is solely based on its resemblance to psoriasis rather than any knowledge of its pathomechanism. Insight into pathogenic mediators of inflammation is essential for targeted and valid treatment op
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff094ba5da47cb3a18fdfc81f5ce727
https://doi.org/10.1001/jamadermatol.2016.5384
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje